MRK WINREVAIR Phase 2 CADENCE trial success

What happened: Merck & Co. (MRK) announced positive results from the Phase 2 CADENCE trial of WINREVAIR™, a potential treatment for pulmonary hypertension. The trial showed that two doses of WINREVAIR (0.3 mg/kg and 0.7 mg/kg) demonstrated proof-of-concept, with positive effects on key parameters such as pulmonary vascular resistance and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Merck reported Q1 2026 revenue of $16.29B, up 5% YoY, with KEYTRUDA sales jumping 12% to $8.03B and WINREVAIR surging 88% to $525M.

Market impact: The successful trial results have driven Merck's stock price higher, as investors anticipate the potential of WINREVAIR™ to expand Merck's oncology portfolio. The positive data also offsets near-term headwinds, such as the $9.0B acquisition charge from the Cidara deal. The pharmaceutical sector has seen a boost, with Merck's peers also experiencing increased investor interest.

What to watch next: Merck's upcoming Phase 3 trials for WINREVAIR™ will be critical in confirming its efficacy and safety. Key dates include the initiation of the Phase 3 trial, expected in 2026, and the release of top-line data, anticipated in 2028. Additionally, investors will closely monitor Merck's quarterly earnings to assess the continued growth of KEYTRUDA and other pipeline drugs.